These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 14963775)

  • 1. [Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire].
    Giner J; Bobes J; Cervera S; Leal C; Baca E; Ibáñez E
    Actas Esp Psiquiatr; 2004; 32(1):1-7. PubMed ID: 14963775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
    J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.
    Kluge M; Wehmeier PM; Dittmann RW; Langer F; Czekalla J; Lehmann M; Kessler FH; Beyenburg S; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):6-12. PubMed ID: 15706459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
    Beasley CM; Sutton VK; Taylor CC; Sethuraman G; Dossenbach M; Naber D
    J Clin Psychopharmacol; 2006 Feb; 26(1):40-4. PubMed ID: 16415704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjectivity in the perception and measurement of quality of life: conceptualization and development of the Seville questionnaire.
    Giner J; Ibáñez E; Franco D; Alarcón RD
    Psychiatr Q; 2008 Dec; 79(4):321-30. PubMed ID: 18839309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Seville Quality of Life Questionnaire: historic outlook of its establishment].
    Giner J; Ibáñez E; Cervera S; Leal C; Baca E; Bobes J
    Actas Esp Psiquiatr; 1999; 27(1):8-13. PubMed ID: 10380142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH; Revicki DA; Genduso LA; Beasley CM
    Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
    Ritsner MS; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1442-52. PubMed ID: 16842897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.
    Higuchi Y; Sumiyoshi T; Kawasaki Y; Matsui M; Arai H; Kurachi M
    Schizophr Res; 2008 Apr; 101(1-3):320-30. PubMed ID: 18321680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients.
    Salín-Pascual RJ; Herrera-Estrella M; Galicia-Polo L; Rosas M; Brunner E
    Rev Invest Clin; 2004; 56(3):345-50. PubMed ID: 15612518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subjective experience and quality of life in schizophrenia].
    Giner J; Ibáñez E; Cervera S; Sanmartín A; Caballero R
    Actas Esp Psiquiatr; 2001; 29(4):233-42. PubMed ID: 11470058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.
    Naber D; Riedel M; Klimke A; Vorbach EU; Lambert M; Kühn KU; Bender S; Bandelow B; Lemmer W; Moritz S; Dittmann RW
    Acta Psychiatr Scand; 2005 Feb; 111(2):106-15. PubMed ID: 15667429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why do physicians switch from one antipsychotic agent to another? The "physician drug stereotype".
    Linden M; Pyrkosch L; Dittmann RW; Czekalla J
    J Clin Psychopharmacol; 2006 Jun; 26(3):225-31. PubMed ID: 16702886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.